{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T20:33:11Z","timestamp":1786653191478,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/1008-682x.168687","type":"journal-article","created":{"date-parts":[[2015,10,30]],"date-time":"2015-10-30T01:42:28Z","timestamp":1446169348000},"page":"286","source":"Crossref","is-referenced-by-count":37,"title":["Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml\n                    <sup>-1<\/sup>"],"prefix":"10.4103","volume":"19","author":[{"given":"LincolnGL","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YungKhan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"BeeChoo","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KarenML","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet","family":"Gauhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HoYee","family":"Tiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RobertCW","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ThomasP","family":"Thamboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FeliciaSK","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Chiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.168687-1","first-page":"87","volume-title":"Global cancer statistics, 2012","author":"Torre","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"key-10.4103\/1008-682X.168687-2","first-page":"977","volume-title":"Global surveillance of cancer survival 1995-2009: analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)","author":"Allemani","year":"2014","journal-title":"Lancet"},{"key":"key-10.4103\/1008-682X.168687-3","first-page":"177","volume-title":"Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen","author":"Chan","year":"2003","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.168687-4","first-page":"1017","volume-title":"Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer","author":"Mikolajczyk","year":"2004","journal-title":"Clin Chem"},{"key":"key-10.4103\/1008-682X.168687-5","first-page":"1228","volume-title":"The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma","author":"Epstein","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"key-10.4103\/1008-682X.168687-6","doi-asserted-by":"publisher","unstructured":"Moyer VA, Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120-34.","DOI":"10.7326\/0003-4819-157-2-201207170-00459"},{"key":"key-10.4103\/1008-682X.168687-7","first-page":"537","volume-title":"Clinical performance of Prostate Health Index (PHI) for prediction of prostate cancer in obese men: data from a multicenter European prospective study, PROMEtheuS project","author":"Abrate","year":"2015","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.168687-8","first-page":"512","volume-title":"Diagnostic ability of %p2PSA and Prostate Health Index for aggressive prostate cancer: a meta-analysis","author":"Wang","year":"2014","journal-title":"Sci Rep"},{"key":"key-10.4103\/1008-682X.168687-9","first-page":"214","volume-title":"Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng ml -1 : results of a prospective study in a clinical setting","author":"Guazzoni","year":"2011","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.168687-10","first-page":"306","volume-title":"Multicenter evaluation of [-2]proprostate-specific antigen and the Prostate Health Index for detecting prostate cancer","author":"Stephan","year":"2013","journal-title":"Clin Chem"},{"key":"key-10.4103\/1008-682X.168687-11","first-page":"921","volume-title":"Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection","author":"Jansen","year":"2010","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.168687-12","first-page":"1193","volume-title":"A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness","author":"Sokoll","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"key-10.4103\/1008-682X.168687-13","first-page":"711","volume-title":"The Prostate Health Index in predicting initial prostate biopsy outcomes in Asian men with prostate-specific antigen levels of 4-10 ng ml -1","author":"Ng","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"key-10.4103\/1008-682X.168687-14","doi-asserted-by":"publisher","unstructured":"Ito K, Miyakubo M, Sekine Y, Koike H, Matsui H, et al. Diagnostic significance of [-2]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0-10.0 ng ml -1 range. World J Urol 2013; 31: 305-11.","DOI":"10.1007\/s00345-012-0927-9"},{"key":"key-10.4103\/1008-682X.168687-15","first-page":"1569","volume-title":"Performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and the Prostate Health Index (PHI) in a Chinese hospital-based biopsy population","author":"Na","year":"2014","journal-title":"Prostate"},{"key":"key-10.4103\/1008-682X.168687-16","first-page":"1029","volume-title":"Detection rates and biologic significance of prostate cancer with PSA less than 4.0 ng ml -1 : observation and clinical implications from Tyrol screening project","author":"Pelzer","year":"2005","journal-title":"Urology"},{"key":"key-10.4103\/1008-682X.168687-17","first-page":"986","volume-title":"Serum isoform [-2]proPSA derivatives significantly improve prediction of prostate cancer at initial biopsy in a total PSA range of 2-10 ng ml -1 : a multicentric European study","author":"Lazzeri","year":"2013","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.168687-18","first-page":"1163","volume-title":"The Prostate Health Index selectively identifies clinically significant prostate cancer","author":"Loeb","year":"2015","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.168687-19","first-page":"65","volume-title":"Multicenter evaluation of the Prostate Health Index (PHI) for detection of aggressive prostate cancer in biopsy-naive men","author":"de","year":"2015","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.168687-20","first-page":"e15","volume-title":"Prognostic accuracy of Prostate Health Index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy","author":"Cantiello","year":"2015","journal-title":"Urol Oncol"},{"key":"key-10.4103\/1008-682X.168687-21","first-page":"132","volume-title":"Preoperative prostate-specific antigen isoform p2PSA and Its derivatives, %p2PSA and Prostate Health Index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer: results from a multicentric European prospective study","author":"Fossati","year":"2014","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.168687-22","first-page":"253","volume-title":"Budget impact analysis of a new prostate cancer risk index for prostate cancer detection","author":"Nichol","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key-10.4103\/1008-682X.168687-23","first-page":"353","volume-title":"Cost-effectiveness of Prostate Health Index for prostate cancer detection","author":"Nichol","year":"2012","journal-title":"BJU Int"},{"key":"key-10.4103\/1008-682X.168687-24","first-page":"926","volume-title":"Pre-analytical in-vitro stability of [-2]proPSA in blood and serum","author":"Semjonow","year":"2010","journal-title":"Clin Biochem"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:33:13Z","timestamp":1786649593000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1008-682X.168687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017]]}},"alternative-id":["168687"],"URL":"https:\/\/doi.org\/10.4103\/1008-682x.168687","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}